Widely available, well covered, and backed by Harrow
Get your patients started
ILEVRO® HAS THE BEST FORMULARY COVERAGE OF ANY BRANDED NSAID*
of patients are covered
of patients are covered
Harrow is committed to helping patients have affordable access to ILEVRO®
Patients pay as little as
Terms and conditions may apply. Copay program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. For full terms and conditions visit www.harrowconnects.com.
ILEVRO® COVERAGE CHECK
Curious about ILEVRO® coverage for patients in your area? The ILEVRO® Policy Lookup Tool has the coverage details and resources you're looking for all in one place, including:
- Up-to-date policy coverages per plan
- Local coverage determinations
- Prior authorization forms
Largest branded ophthalmic NSAID clinical trial program1-3‡
Stay connected with us
Data provided through MMIT and are current as of 2/2024. The information provided in this website is not a guarantee of coverage or payment (partial or full). Actual benefits are determined by each plan administrator in accordance with its respective policy and procedures. Nothing herein may be construed as an endorsement, approval, recommendation, representation or warranty of any kind by any plan or insurer referenced herein.
Since 2005.
References: 1. ILEVRO (nepafenac ophthalmic suspension) 0.3% [package insert]. Harrow IP, LLC; 2023. 2. BromSite (bromfenac ophthalmic solution) 0.075% [package insert]. Cranbury, NJ: Sun Pharma Global FZE; 2016. 3. Prolensa (bromfenac ophthalmic solution) 0.07% [package insert]. Bridgewater, NJ: Bausch & Lomb; 2016.